Thrombotic complications emerged as an important issue in patients with coronavirus disease 2019 (COVID-19). Consolidated reports regarding the clinical and laboratory findings in COVID-19 patients reveal thrombocytopenia, elevated D-dimer, prolonged prothrombin time, disseminated intravascular coagulation, and pulmonary intravascular coagulation (PIC). Recently, some authors emphasized the potential role of antiphospholipid antibodies in the pathogenesis of thrombotic events in patients with severe COVID-19.
Multifactorial pathogenesis of COVID-19-related coagulopathy. Can defibrotide have a role in the early phases of coagulation disorders?
Macciò, AntonioPrimo
;Madeddu, Clelia
Secondo
;Caocci, GiovanniPenultimo
;La Nasa, GiorgioUltimo
2020-01-01
Abstract
Thrombotic complications emerged as an important issue in patients with coronavirus disease 2019 (COVID-19). Consolidated reports regarding the clinical and laboratory findings in COVID-19 patients reveal thrombocytopenia, elevated D-dimer, prolonged prothrombin time, disseminated intravascular coagulation, and pulmonary intravascular coagulation (PIC). Recently, some authors emphasized the potential role of antiphospholipid antibodies in the pathogenesis of thrombotic events in patients with severe COVID-19.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Multifactor pathogenesis of COVID-19-related coagulopathy.pdf
accesso aperto
Tipologia:
versione pre-print
Dimensione
3.45 MB
Formato
Adobe PDF
|
3.45 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
